№ files_lp_4_process_2_79222
File format: docx
Character count: 10466
File size: 110 KB
Bulletin detailing new additions, prior authorization changes, and updates to the MassHealth drug list including the Concomitant Opioid and Benzodiazepine Initiative for prescribers and pharmacies.
Year:
2019
Region / City:
Massachusetts, USA
Subject:
Pharmaceutical policy updates
Document Type:
Update bulletin
Organization:
MassHealth
Effective Dates:
November 8, 2019 – November 25, 2019
Medications Added:
Zolgensma, Abilify Mycite, Adhansia XR, Apadaz, Evekeo ODT, Inbrija, Jornay PM, Katerzia, Krintafel, Minolira, Polivy, Prograf, Qmiiz, Rozlytrek, Sunosi, Triluron, Vyndamax
Changes in Prior Authorization:
Benzodiazepines with opioids, Proton pump inhibitors, Influenza treatments
Brand Name Preferred Updates:
Dexilant added, Voltaren Gel removed
Abbreviations:
PA – Prior Authorization, BP – Brand Preferred, CO – Carve-Out, PD – Preferred Drug
Target Audience:
Healthcare providers prescribing MassHealth-covered medications
Implementation Date:
November 25, 2019
Reference Website:
www.mass.gov/druglist
Updates Type:
Additions, deletions, PA changes, policy clarifications
Clinical Focus:
Concomitant opioid and benzodiazepine usage and safe prescribing requirements
Regulatory Context:
FDA “A”-rated generic equivalents and MassHealth formulary requirements
Healthcare Impact:
Affects MassHealth members outside MCO plans
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Subject:
Concomitant medications tracking
Document Type:
Template
Organization / Institution:
NIMH
Target Audience:
Principal Investigators, study team members
Year:
2019
Institution:
Utah State University
Location:
Logan, Utah
Author:
Linda K. Todd
Degree:
Doctor of Philosophy; Master of Science
Field of Study:
Psychology
Document Type:
Dissertation and Thesis Submission Pages
Approving Authority:
Richard S. Inouye, Ph.D., Vice Provost for Graduate Studies
Academic Level:
Graduate
Subject Focus:
Diagnosis of Anorexia Nervosa, Bulimia Nervosa, and Concomitant Conditions
Related Conditions:
Anorexia nervosa; Bulimia nervosa
Year:
2023
Region / city:
International
Topic:
Cardiovascular research
Document type:
Scientific appendix
Organization:
REDWOOD-HCM, SEQUOIA-HCM, FOREST-HCM Investigators
Author:
Ahmad Masri, MD, MS; Martin S. Maron; Theodore P. Abraham, MD; Michael E. Nassif, MD; Roberto Barriales-Villa, MD; Ozlem Bilen, MD; Caroline J. Coats, MD, PhD; Perry Elliott, MBBS, MD; Pablo Garcia-Pavia, MD PhD; Daniele Massera, MD; Iacopo Olivotto, MD; Artur Oreziak, MD, PhD; Anjali Tiku Owens, MD; Sara Saberi, MD, MS; Scott D. Solomon, MD; Albree Tower-Rader, MD; Stephen B. Heitner, MD; Daniel L. Jacoby, MD; Chiara Melloni, MD, MS; Jenny Wei, PhD; MD; Mark V. Sherrid, MD
Target audience:
Cardiologists, researchers in cardiovascular medicine
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Year
Document Type:
CRF (Case Report Form)
Target Audience:
Research teams, Clinical Study Personnel
Period of Use:
Ongoing during the study
Jurisdiction:
Clay County, Missouri
Type of document:
Charter
Subject matter:
Opioid settlement fund governance
Purpose:
Advisory oversight and recommendations on opioid settlement fund allocation
Funding source:
Opioid Settlement Agreement
Total settlement amount:
Approximately $1,444,623.26
Funding period:
18 years
Annual allocation:
Approximately $80,000
Governing body:
Clay County Commission
Advisory body:
Clay County Opioid Settlement Task Force
Membership size:
9 members
Appointing authority:
Presiding Commissioner with consent of the Governing Body
Meeting openness:
Open to the public
Public notice law:
Missouri Open Records Act
Meeting location:
Clay County Administration, 1 Courthouse Square, Liberty, Missouri
Reporting requirement:
Formal report and proposed plan submitted to the Commission
Termination condition:
Approval of an opioid settlement utilization plan by the Clay County Commission
Year:
2023
Region / City:
Pinal County, Arizona
Topic:
Opioid Settlement Funding, Community Health Programs
Document Type:
Guidelines
Agency:
Pinal County Public Health Services District
Target Audience:
Nonprofit Organizations, Community-Based Organizations, Healthcare Providers
Period of Validity:
September 22, 2025
Approval Date:
July 12, 2023
Date of Changes:
-
Year:
2021
Region / City:
Richmond, VA
Topic:
Opioid overdose, Naloxone
Document Type:
Instructional Guide
Organization:
Virginia Department of Behavioral Health and Developmental Services
Author:
N/A
Target Audience:
General public, individuals attending REVIVE! training
Effective Date:
N/A
Date of Last Revision:
September 2021
Year:
2023
Country:
Australia
Topic:
Opioid dependence treatment
Document type:
Information overview
Program:
ODT Community Pharmacy Program
Administering body:
Pharmacy Programs Administrator
Related scheme:
Pharmaceutical Benefits Scheme
Legislative framework:
National Health (Highly specialised drugs program) Special Arrangement 2021
Target audience:
Community pharmacists and hospital pharmacists
Effective date:
1 July 2023
Funding period:
2023–24 to 2026–27
Medicines covered:
Methadone, buprenorphine, buprenorphine with naloxone
Regulatory classification:
Schedule 8 controlled drugs
Source type:
Government health program guidance
Year:
2025
Region / City:
Massachusetts, Boston
Topic:
Healthcare, Opioid Use Disorder, Long-Term Care
Document Type:
Memorandum
Organization / Institution:
Department of Public Health
Author:
Teryl Smith, RN, MPH
Target Audience:
Long-Term Care Facility Administrators
Period of Validity:
August 14, 2025
Approval Date:
August 14, 2025
Date of Changes:
August 14, 2025
Year:
2022
Region / City:
Massachusetts
Subject:
Opioid Use Disorder, Long-Term Care Facilities
Document Type:
Memorandum
Agency:
Massachusetts Executive Office of Health and Human Services, Department of Public Health
Author:
Elizabeth Kelley, MPH, MBA, Director Bureau of Health Care Safety and Quality
Target Audience:
Long-Term Care Facility Administrators
Period of Validity:
September 12, 2022
Approval Date:
September 12, 2022
Year:
2019–2020
Country:
England
Thematic area:
Opioid prescribing and medicines safety
Document type:
Technical specification
Related programme:
Prescribed Medicines Review
Issuing bodies:
NHS Business Services Authority; Wessex Academic Health Science Network
Contributing organisations:
Public Health England; Medicines and Healthcare products Regulatory Agency
Intended audience:
Healthcare professionals; NHS organisations
Data sources:
NHS prescribing data; Electronic Prescribing System
Medicine classifications used:
British National Formulary
Appendices included:
Medicine classes; Oral Morphine Equivalent values; Working groups
Year:
2023
Region / City:
Massachusetts
Topic:
Opioid Use Disorder, Medication Comparison
Document Type:
Clinical Guidelines
Organization / Institution:
Massachusetts Department of Public Health, Bureau of Health Care Safety & Quality
Author:
Massachusetts Department of Public Health
Target Audience:
Healthcare providers, Long-Term Care Facilities
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Department:
Department of Health and Mental Hygiene
Administration:
Behavioral Health Administration
Workgroup:
Opioid Treatment Program (OTP) Quality Improvement Workgroup
Date:
September 13, 2016
Document type:
Meeting minutes
Location:
Not specified
Attendees:
K. Rebbert-Franklin; C. Trenton; L. Burns-Heffner; B. Page; M. Donohue; F. Dyson; E. Hall; G. Ott; H. Ashkin; A. Breidensteine; M. Currens; S. Drennan; C. Halpin; D. Hodge; Y. Israel; D. Madden; A. Mlinarchik; Y. Olsen; J. Severn; K. Stoller; B. Wahl; V. Walters; A. Winepol
Participants by phone:
R. Faulkner; M. Viggiani; J. Formicola; V. Waters
Primary topic:
Development of quality standards for opioid treatment programs
Related programs:
Methadone treatment; Buprenorphine treatment
Key themes:
Staffing ratios; multidisciplinary teams; patient outcomes; care coordination; training; hours of operation; medical coverage
Related agencies:
Beacon Health Options; Board of Professional Counselors; SAMHSA; CARF
Regulatory context:
DHMH regulations; PDMP legal requirements
Year:
2025
Region / City:
Yates County, New York
Theme:
Opioid Use Disorder, Community Health
Document Type:
Funding Application
Organ / Institution:
Yates County
Author:
Yates County
Target Audience:
Non-profits, municipalities, schools, healthcare institutions, for-profit businesses, government entities
Period of Validity:
September 15, 2025 – December 31, 2026
Approval Date:
N/A
Date of Amendments:
N/A
Year:
2023
Region / City:
Tennessee
Topic:
Opioid Crisis, Community Funding
Document Type:
Application Form
Organization:
Tennessee Department of Health, Opioid Abatement Council
Author:
N/A
Target Audience:
Non-profit organizations, healthcare providers
Effective Period:
October 16, 2023, 11:59 p.m. CDT
Approval Date:
N/A
Modification Date:
N/A
Year:
Not specified
Region / city:
Not specified
Topic:
Long-Term Opioid Therapy
Document type:
Informed Consent Form
Organization / institution:
VA (Veterans Affairs)
Author:
Not specified
Target audience:
Patients receiving opioid therapy for chronic pain
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Context:
Informed consent document outlining the risks, benefits, and conditions of long-term opioid therapy for chronic pain management.
Year:
2024
Region / city:
Australia
Theme:
Opioid dependence treatment, Pharmaceutical Benefits Scheme
Document type:
FAQ
Organization / institution:
Pharmaceutical Benefits Scheme
Author:
Pharmaceutical Benefits Scheme
Target audience:
Healthcare providers, prescribers, pharmacists
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2015
Region / City:
Maine
Topic:
Controlled Substances Prescription Monitoring, Opioid Medications
Document Type:
Regulations
Agency:
Department of Health and Human Services, Office of Substance Abuse and Mental Health Services
Author:
Maine Department of Health and Human Services
Target Audience:
Healthcare providers, pharmacists, prescribers, dispensers
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Amendments:
Not specified
Note:
Contextual description
Note:
Year
Topic:
Opioid Therapy
Document Type:
Agreement
Target Audience:
Patients prescribed opioid medication